Product Description
Darzalex (daratumumab) is the first FDA-approved monoclonal antibody that targets the CD38 protein on the surface of myeloma cells. (Sourced from: https://www.myeloma.org/darzalex-daratumumab)
Mechanisms of Action: CD38 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous, Subcutaneous
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Johnson & Johnson
Company Location: Eastern America
Company Founding Year: 1886
Additional Commercial Interests: Genmab
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Russia, Singapore, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 127
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Johnson & Johnson presented P3 Multiple Myeloma results on 2025-06-03 for Daratumumab
- Clinical Outcomes Reported - Johnson & Johnson presented P3 Multiple Myeloma results on 2024-12-08 for Daratumumab
- Clinical Outcomes Reported - Johnson & Johnson presented P3 Multiple Myeloma results on 2024-09-27 for Daratumumab
Highest Development Phases
Phase 3: Amyloidosis|Bone Cancer|Multiple Myeloma
Phase 2: Acute Lymphoid Leukemia|Alzheimer Disease|Anemia, Sickle Cell|Antiphospholipid Syndrome|Arthritis, Rheumatoid|Blood Protein Disorders|Chronic Lymphoid Leukemia|Conduct Disorder|Glomerulonephritis|Heart Transplant|Kidney Diseases|Kidney Transplant|Large-Cell Immunoblastic Lymphoma|Lupus Erythematosus, Systemic|Lymphocytic Chronic B-Cell Leukemia|Monoclonal Gammopathy of Undetermined Significance|POEMS Syndrome|Paraproteinemias|Plasmablastic Lymphoma|Plasmacytoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Stevens-Johnson Syndrome|T-Cell Leukemia
Phase 1: Acute Myeloid Leukemia|Anemia, Aplastic|Bladder Cancer|Chronic Myeloid Leukemia|Diffuse Large B-Cell Lymphoma|Kidney Cancer|Myelodysplastic Syndrome|Myelofibrosis|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Preleukemia|Renal Cell Carcinoma|Stem Cell Transplant|Transitional Cell Carcinoma|Urologic Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04139304 |
AMC-105 | P1 |
Recruiting |
Diffuse Large B-Cell Lymphoma|Large-Cell Immunoblastic Lymphoma|Plasmablastic Lymphoma |
2029-07-01 |
50% |
2025-07-01 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT06398457 |
J2450 | P1 |
Recruiting |
Myelodysplastic Syndrome|Chronic Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Preleukemia|Chronic Myeloid Leukemia|Acute Lymphoid Leukemia|Multiple Myeloma|Acute Myeloid Leukemia|Anemia, Aplastic|Stem Cell Transplant|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Myelofibrosis |
2026-09-01 |
12% |
2024-09-26 |
Primary Endpoints|Start Date |
NCT06142396 |
54767414MMY2095 | P1 |
Recruiting |
Multiple Myeloma|Kidney Diseases |
2025-11-01 |
50% |
2025-02-22 |
Primary Endpoints|Start Date |
NCT03473730 |
NCI-2018-00800 | P1 |
Completed |
Transitional Cell Carcinoma|Urologic Cancer|Kidney Cancer|Bladder Cancer|Renal Cell Carcinoma |
2025-01-27 |
67% |
2025-01-31 |
|
NCT06358638 |
SUN-RAY | P2 |
Recruiting |
Anemia, Sickle Cell |
2044-09-01 |
12% |
2025-08-27 |
Primary Endpoints|Start Date|Treatments |
NCT07075510 |
2513GCCC | P2 |
Recruiting |
Conduct Disorder|Amyloidosis|Multiple Myeloma |
2030-10-01 |
12% |
2025-10-30 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT07110662 |
NET-CD38 | P2 |
Not yet recruiting |
Stevens-Johnson Syndrome |
2028-10-29 |
12% |
2025-08-08 |
|
NCT05289687 |
EA9213 | P2 |
Recruiting |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia|T-Cell Leukemia |
2027-06-30 |
12% |
2024-12-13 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT06889948 |
DAMOCLES | P2 |
Recruiting |
Kidney Diseases|Glomerulonephritis|Paraproteinemias|Monoclonal Gammopathy of Undetermined Significance |
2027-06-01 |
2025-03-22 |
Primary Endpoints |
|
NCT04827979 |
ATTAIN | P2 |
Active, not recruiting |
Kidney Transplant |
2027-03-31 |
12% |
2026-01-21 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
NCT04166565 |
EMN19 | P2 |
Active, not recruiting |
Plasmacytoma|Multiple Myeloma |
2027-03-01 |
12% |
2024-01-31 |
Primary Endpoints|Treatments |
NCT04270175 |
NCT04270175 | P2 |
Active, not recruiting |
Amyloidosis|Alzheimer Disease |
2027-01-01 |
12% |
2026-02-28 |
|
NCT03236428 |
NCT03236428 | P2 |
Active, not recruiting |
Paraproteinemias|Multiple Myeloma|Monoclonal Gammopathy of Undetermined Significance |
2026-10-04 |
12% |
2022-09-22 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT05300451 |
NCT05300451 | P2 |
Enrolling by invitation |
Heart Transplant |
2026-08-01 |
12% |
2025-10-31 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT05671757 |
DARE-APS | P2 |
Recruiting |
Antiphospholipid Syndrome |
2026-06-24 |
12% |
2024-11-30 |
|
NCT05280275 |
EAE 120 | P2 |
Recruiting |
Blood Protein Disorders|Paraproteinemias|Multiple Myeloma |
2026-03-15 |
49% |
2023-12-02 |
Primary Endpoints|Start Date|Treatments|Trial Status |
2021-006669-40 |
CURACTA | P2 |
Active, not recruiting |
Arthritis, Rheumatoid |
2026-01-31 |
|||
NCT04915248 |
FIL_DALYA | P2 |
Recruiting |
Plasmablastic Lymphoma|Large-Cell Immunoblastic Lymphoma |
2026-01-01 |
12% |
2025-07-17 |
|
2021-000962-14 |
DARALUP | P2 |
Completed |
Lupus Erythematosus, Systemic |
2024-07-25 |
19% |
2025-07-09 |
Treatments |
NCT04396496 |
NCT04396496 | P2 |
Completed |
POEMS Syndrome |
2023-08-29 |
37% |
2023-11-14 |
Primary Endpoints |
NCT03734198 |
IDA53 | P2 |
Active, not recruiting |
Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia |
2023-06-17 |
37% |
2024-11-01 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
2023-507143-11-00 |
54767414SMM3001 | P3 |
Active, not recruiting |
Bone Cancer |
2025-12-10 |
2025-05-02 |
Treatments |
|
2025-520897-21-00 |
M25-586 | P3 |
Not yet recruiting |
Multiple Myeloma |
2042-02-28 |
|||
NCT07095452 |
M25-586 | P3 |
Recruiting |
Multiple Myeloma |
2042-01-01 |
15% |
2026-01-28 |
Primary Completion Date|Primary Endpoints |
NCT06932562 |
EMN39 | P3 |
Recruiting |
Multiple Myeloma |
2036-12-01 |
54% |
2025-12-06 |
Primary Endpoints|Start Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/16/2026 |
News Article |
Idaho Housing and Finance Association (IHFA) Expands Partnership with Sagent, Adopts Full Dara Platform to Power End-to-End Mortgage Servicing |
|
02/16/2026 |
News Article |
Click n' Close to Deploy Dara by Sagent to Power Core, Consumer, and Default Servicing |
|
02/16/2026 |
News Article |
The coffee industry already knows the World's 100 Best Coffee Shops |
|
02/10/2026 |
News Article |
Wip and Bossi Introduce Ultra-Limited Capsule Bringing Energy Culture Into Luxury Streetwear |